Chemoinformatics Market Report 2025

The chemoinformatics market size has grown marginally in recent years. It will grow from $4.29 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 1.6%. The growth in the historic period can be attributed to high throughput screening (hts), data availability, drug discovery efficiency, personalized medicine, artificial intelligence (ai) and machine learning.

The chemoinformatics market size is expected to see steady growth in the next few years. It will grow to $5.21 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to biological data integration, structural biology, data management and security, regulatory compliance, drug discovery efficiency. Major trends in the forecast period include high-throughput screening, structural biology integration, biological data mining, virtual chemical libraries, personalized medicine.

The chemoinformatic market is anticipated to experience significant growth, driven by several key factors. The rising prevalence of chronic diseases is identified as a major catalyst for the growth of this market. Chronic diseases, which require ongoing medical attention and last for a year or longer, are becoming increasingly common. Neglected tropical diseases, in particular, demand new drug discoveries and the exploration of novel chemicals for treatment, for which chemoinformatics is a valuable tool. The World Health Organization projects a significant increase in chronic diseases such as obesity, diabetes, heart diseases, and other noncommunicable diseases between 2020 and 2030. The urgent need for new treatments and drug discoveries to address these health challenges is expected to drive the demand for the chemoinformatic market.

The increasing demand for personalized medicine is anticipated to drive the growth of the chemoinformatic market in the future. Personalized medicine customizes medical treatment based on an individual's unique genetic profile, providing more effective and precise healthcare solutions. Chemoinformatic plays a vital role in personalized medicine by analyzing patients' genetic and molecular data to tailor drug therapies, thereby improving treatment efficacy and safety. For example, in 2022, the Personalized Medicine Coalition, a US-based professional membership organization, reported that the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs). Among the 35 therapeutic NMEs, approximately 34%, or 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Thus, the growing demand for personalized medicine is fueling the expansion of the chemoinformatic market.

Technological advancements are a significant trend gaining traction in the chemoinformatic market. Leading companies in the sector are creating software and platforms that incorporate advanced technologies to maintain their competitive edge. For example, in March 2023, NVIDIA Corporation, a US-based technology firm, launched the BioNeMo Cloud service, which features domain-specific generative AI models for drug development. This service enables researchers to customize and refine models according to their specific requirements, assisting companies like AstraZeneca and Evozyne in creating innovative protein designs. The introduction of the BioNeMo Cloud Service marks a revolutionary development in drug discovery, facilitating faster and more efficient research by offering tools that simplify the identification of drug targets and enhance molecular designs. By leveraging advanced generative AI models, researchers can considerably decrease the time and costs linked to traditional drug development methods, potentially accelerating progress in therapeutic solutions.

Major players in the chemoinformatics market are strategically focusing on the development of software equipped with the capability to animate and share 3D chemical structures, aiming to gain a competitive advantage. This kind of software plays a crucial role in visualizing molecular interactions, thereby enhancing research and communication in the field of chemistry. An example of such innovation is seen in the March 2022 release of the latest version of ChemDraw software, V21, by PerkinElmer Inc., a prominent US-based provider of reagents, instruments, assay platforms, and software for medical professionals and researchers. This updated version introduces a significant enhancement by enabling researchers to efficiently generate chemically intelligent Microsoft PowerPoint reports. The key feature of this version is the seamless incorporation, animation, and distribution of 3D chemical structures directly within Microsoft PowerPoint with a single click. This functionality empowers chemists to produce more insightful research reports, facilitating information sharing, collaboration, and real-time decision-making.

In a strategic move, Cadence Design Systems, a US-based computer software company, acquired OpenEye Scientific Software in September 2022 for an undisclosed amount. This acquisition aligns with Cadence's Intelligent System DesignTM strategy, extending its computational software core expertise to molecular modeling and simulation in the life sciences. OpenEye Scientific Software, a US-based software company, specializes in providing molecular modeling and cheminformatics software tools. The acquisition positions Cadence to advance its capabilities in the rapidly evolving field of molecular modeling and simulation, showcasing the integration of software tools crucial for advancing research and innovation in life sciences.

Major companies operating in the chemoinformatics market include ChemAxon Ltd., Jubilant Biosys Inc., BIOVIA, OpenEye Scientific Software Inc., Schrödinger Inc., Advanced Chemistry Development Inc, Scilligence Corporation, Dassault Systemes SE, Chemical Computing Group Inc, Collaborative Drug Discovery Inc., UVJ Technologies, KNIME.COM Aktiengesellschaft, Simulations Plus Inc., Agilent Technologies Inc., Cambridgesoft Corp., Molecular Discovery Ltd., Optibrium Ltd., Cresset Group Ltd., Dotmatics Ltd., Genedata AG, Inte:Ligand GmbH, MolPort Inc., PerkinElmer Inc., Cheminformatics LLC, Chemspace, InfoChem GmbH, Molecular Networks GmbH, VLife Sciences Technologies Pvt. Ltd., Xemistry GmbH, Cheminnovation Software Inc.

Chemoinformatics refers to an emerging field within information technology that focuses on the collection, storage, analysis, and manipulation of chemical data. It is particularly employed to examine the relationships between target molecular activity, chemical characteristics, and structure.

The primary domains encompassed by chemoinformatics are chemistry, computer science, and information science. In the realm of chemistry, chemoinformatics aids in comprehending the physical, chemical, and biological characteristics of diverse chemical compounds, with the added benefit of expediting the identification of potential therapeutic targets. Various applications of chemoinformatics include chemical analysis, drug discovery and validation, virtual screening, among others. These applications find utility in sectors such as chemical and pharmaceutical industries, research and academic institutions, and other end-users.

The chemoinformatics market research report is one of a series of new reports that provides chemoinformatics market statistics, including chemoinformatics industry global market size, regional shares, competitors with chemoinformatics market share, detailed chemoinformatics market segments, market trends, and opportunities, and any further data you may need to thrive in the chemoinformatics industry. This chemoinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the chemoinformatics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemoinformatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemoinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The chemoinformatic market includes revenues earned by entities by developing and providing chemoinformatic tools and software used in the data analysis and drug discovery processes by pharmaceuticals. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.